02157.HK
Lepu Biopharma Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 3.07
−5.26%Oct 27, 2026, 04:29 UTC
Lepu Biopharma Co., Ltd. chairman and controlling shareholder Pu Zhongjie bought 1.05 million H shares on the open market at an average price of about RMB 3.04 (HK$3.55) per share.
Oct 26, 2026, 10:00 UTC
Eikon Therapeutics, Inc. presented updated EIK1001 data from the TeLuRide-005 study at the 2026 ESMO Congress.
Source:Oct 26, 2026, 08:58 UTC
Lepu Biopharma Co., Ltd. reported positive topline results from the global Phase III CLARITY-Gastric01 trial, with sonesitatug vedotin showing a significant overall-survival benefit versus investigator’s choice in both the third-line-and-later and intention-to-treat populations, with manageable safety.
Source:Oct 20, 2026, 08:12 UTC
Hong Kong-listed shares had mixed moves, including Alibaba down 3.6% and Lenovo Group Ltd. down 10%, while Hansoh Pharmaceutical rose 8.3%; Luxxu Group Ltd. and Chervon Holdings Ltd. reached record highs.
Source:Sep 21, 2026, 02:51 UTC
Hong Kong-listed innovative pharmaceutical stocks rose, with Akeso up 7.9% to HK$97.65, GenScript Biotech up 4.68% to HK$41.18, and other Chinese biopharma shares posting gains of over 7% to 9%.
Source:Aug 19, 2026, 08:42 UTC
Lepu Biopharma announced its interim results for the six months ended June 2026, with revenue of RMB 522 million, up 12.1% year-on-year, and net profit of RMB 27.39 million, down 34.4% year-on-year.
Source: